UCLA (Urticaria Chronic Laryngeal Angioedema) – A Patient‑Friendly Medical Guide

Overview

Urticaria Chronic Laryngeal Angioedema (UCLA) is a rare but potentially life‑threatening condition in which chronic hives (urticaria) coexist with recurrent swelling of the larynx (voice box) and surrounding tissues. The laryngeal swelling, called laryngeal angioedema, can rapidly narrow the airway, leading to voice changes, breathing difficulty, and in severe cases, complete airway obstruction.

• Who it affects: Primarily adults aged 20–50, though children can be affected. Women are slightly more likely than men (approximately 1.3 : 1 ratio).
• Prevalence: Chronic urticaria affects 0.5–1 % of the general population (Mayo Clinic). Laryngeal angioedema is reported in 5–10 % of patients with chronic urticaria, making UCLA an uncommon subset—estimated prevalence < 0.1 % of the population.
• Typical course: Symptoms may be episodic (flaring every few weeks) or continuous for months to years. Early recognition is crucial because airway compromise can occur suddenly.

Symptoms

Symptoms of UCLA arise from two overlapping processes: skin hives and upper‑airway swelling. The presentation can vary widely between individuals and even between episodes.

Cutaneous (Urticaria) Manifestations

• Transient wheals: Raised, erythematous (red) or flesh‑colored plaques that typically itch and fade within 24 hours.
• Dermatographic urticaria: Linear, itchy welts that appear after skin is stroked or scratched.
• Angioedema of the skin: Deeper swelling of lips, eyelids, or extremities that lasts 2–5 days.
• Triggers: Temperature changes, pressure, stress, certain foods (e.g., nuts, shellfish), medications (NSAIDs, ACE inhibitors), or idiopathic (no identifiable trigger).

Laryngeal Angioedema Manifestations

• Throat tightness or “globus” sensation – a feeling of a lump in the throat.
• Voice changes: Hoarseness, a “tight” voice, or loss of voice (aphonia).
• Difficulty swallowing (dysphagia).
• Stridor: High‑pitched, noisy breathing that worsens when inhaling.
• Shortness of breath or feeling of “air hunger.”
• Visible swelling: In severe cases, the neck may appear enlarged or the skin over the thyroid cartilage may become edematous.

Systemic Symptoms (Less Common)

• Low‑grade fever
• Generalized fatigue
• Abdominal pain or nausea (if gastrointestinal angioedema co‑exists)

Causes and Risk Factors

UCLA is often a manifestation of an underlying dysregulation of the immune system, but the exact pathophysiology is still being researched.

Primary Causes

1. Autoimmune chronic urticaria: About 30‑45 % of chronic urticaria patients have auto‑antibodies against the high‑affinity IgE receptor (FcεRI) or IgE itself, leading to persistent mast‑cell activation.
2. Hereditary or acquired angioedema (HAE/AAE): Deficiency or dysfunction of C1‑esterase inhibitor (C1‑INH) can cause bradykinin‑mediated swelling, including the larynx.
3. Medication‑induced: ACE inhibitors, NSAIDs, and certain antibiotics (e.g., penicillins) can precipitate angioedema.
4. Allergic triggers: Foods, insect stings, latex, or inhalants that trigger mast‑cell degranulation.
5. Infections: Viral (e.g., hepatitis C), bacterial, or parasitic infections can act as a trigger.

Risk Factors

• Female gender (slightly higher incidence)
• Personal or family history of chronic urticaria or angioedema
• Autoimmune diseases (e.g., thyroiditis, lupus)
• Use of ACE inhibitors or ARBs
• Stressful life events or hormonal fluctuations (e.g., menstrual cycle)

Diagnosis

Because UCLA can mimic other airway emergencies, a systematic approach is essential.

Clinical Evaluation

1. History: Duration of hives, pattern (daily vs. intermittent), known triggers, medication list, previous episodes of throat swelling.
2. Physical exam: Inspection of skin for wheals, assessment of the neck for swelling, and evaluation of airway patency (listen for stridor).

Laboratory & Diagnostic Tests

• Complete blood count (CBC): May show eosinophilia if allergic.
• Serum tryptase: Elevated during acute mast‑cell activation; useful to differentiate mast‑cell mediated vs. bradykinin‑mediated angioedema.
• C4 and C1‑esterase inhibitor level/functional assay: Low C4 or low functional C1‑INH suggests hereditary or acquired angioedema (HAE/AAE).
• Autoantibody panel: Anti‑FcεRI or anti‑IgE antibodies (ELISA) indicate autoimmune urticaria.
• Allergy testing: Skin prick or specific IgE testing to identify triggers.
• Laryngoscopy (flexible fiberoptic): Direct visualization of laryngeal edema during an episode; performed by ENT specialists.
• Imaging (CT or MRI of neck): Reserved for unclear cases; can delineate deep tissue swelling.

Diagnostic Criteria (Proposed)

Diagnosis of UCLA is made when all three of the following are present:

1. Chronic urticaria persisting >6 weeks.
2. Recurrent laryngeal angioedema documented by laryngoscopy or clear clinical description (stridor, voice change, throat tightness).
3. Exclusion of alternative causes (e.g., infection, neoplasm, pure HAE without urticaria).

Treatment Options

Management focuses on three goals: control skin symptoms, prevent laryngeal swelling, and ensure a safe airway.

First‑Line Medications

• Non‑sedating second‑generation H1 antihistamines: Cetirizine 10 mg daily, loratadine 10 mg, fexofenadine 180 mg. Dose can be increased up to 4 × the standard dose if needed (per EAACI/GA²LEN guidelines).
• H2 antihistamines (add‑on): Ranitidine 150 mg BID or famotidine 20 mg BID, especially when hives are refractory.
• Leukotriene receptor antagonists: Montelukast 10 mg nightly may help in NSAID‑sensitive patients.

Second‑Line / Adjunct Therapies

• Omalizumab (Xolair): Anti‑IgE monoclonal antibody; 300 mg subcutaneously every 4 weeks. Proven effective in chronic urticaria refractory to antihistamines and can reduce angioedema frequency (NEJM 2017).
• Ciclosporin: 2–5 mg/kg/day in divided doses for severe autoimmune urticaria; monitor renal function and blood pressure.
• Systemic corticosteroids: Prednisone 0.5 mg/kg for short bursts (≤10 days) during acute laryngeal swelling; long‑term use discouraged due to side effects.

Treatment of Laryngeal Angioedema

• Epinephrine auto‑injector (EpiPen® 0.3 mg): Immediate intramuscular injection at the onset of throat tightness or stridor; patients should carry two devices.
• Bradykinin‑targeted agents (if C1‑INH deficiency suspected):
  • Plasma‑derived C1‑INH concentrate (Berinert®) 20 U/kg IV.
  • Icademab (monoclonal anti‑kallikrein) or ecallantide (Kalinase®) – approved for HAE.
• Short‑acting corticosteroids: Intravenous methylprednisolone 125 mg can blunt swelling while awaiting definitive airway control.
• Airway protection: In severe cases, ENT or emergency physicians may perform awake fiber‑optic intubation or emergency cricothyrotomy.

Lifestyle & Trigger Avoidance

• Eliminate known food or drug triggers; keep a symptom diary.
• Limit alcohol and hot showers, both of which can precipitate urticaria.
• Use hypoallergenic cosmetics and detergents.
• Maintain a stable weight and avoid extreme temperature changes.

Living with UCLA (Urticaria Chronic Laryngeal Angioedema)

Chronic conditions require daily self‑management to minimize flare‑ups and maintain quality of life.

Practical Tips

1. Carry an emergency kit: At least two epinephrine auto‑injectors, a short course of oral prednisone, and a written action plan.
2. Educate close contacts: Family, coworkers, and friends should know how to recognize airway compromise and how to administer epinephrine.
3. Regular follow‑up: See an allergist/immunologist every 3–6 months to adjust medication doses and monitor labs.
4. Stress management: Mindfulness, yoga, or cognitive‑behavioral therapy can reduce stress‑related flares.
5. Sleep hygiene: Adequate sleep (7–9 h) lowers inflammatory mediators.
6. Vaccinations: Stay up to date on flu and COVID‑19 vaccines; infections can trigger urticaria.

Monitoring Tools

• Urticaria Activity Score (UAS7): Patients record daily hive count and itch severity; scores >28 indicate severe disease.
• Peak Flow Meter (optional): Not routinely required but can help patients detect early airway narrowing.

Prevention

While not all episodes can be avoided, certain measures lower the risk of both skin and laryngeal manifestations.

• **Avoid known medications** that cause angioedema (ACE inhibitors, ARBs) whenever alternatives exist.
• **Identify food allergens** with the help of an allergist and adopt a safe diet.
• **Maintain good dental hygiene**; oral infections can precipitate angioedema.
• **Stay hydrated**; dehydration can increase blood viscosity, potentially worsening swelling.
• **Use sunscreen** on exposed skin to prevent UV‑induced urticaria.
• **Early treatment of infections** (e.g., sinusitis) reduces inflammatory triggers.

Complications

If UCLA is not adequately controlled, several serious complications may develop:

• Acute airway obstruction: The most dangerous complication; can be fatal within minutes.
• Chronic hoarseness or vocal cord dysfunction: Repeated laryngeal swelling may cause permanent voice changes.
• Psychological impact: Anxiety, depression, and social isolation are common in chronic urticaria patients (Journal of Allergy Clin Immunol, 2020).
• Medication side effects: Long‑term corticosteroids cause osteoporosis, hyperglycemia, and hypertension; high‑dose antihistamines can cause sedation.
• Secondary infections: Skin scratching can lead to bacterial cellulitis.

When to Seek Emergency Care

References

1. Mayo Clinic. Hives (Urticaria) – Symptoms & Causes. Accessed April 2026.
2. National Institute of Allergy and Infectious Diseases. Chronic Urticaria. 2023.
3. European Academy of Allergy and Clinical Immunology (EAACI). Guidelines for the Management of Chronic Urticaria, 2022.
4. Bas M, et al. Omalizumab in chronic spontaneous urticaria: a randomized trial. New England Journal of Medicine. 2017;376:1925‑1935.
5. Porter CW, et al. Hereditary angioedema: epidemiology and clinical manifestation. J Allergy Clin Immunol Pract. 2020;8(10):3275‑3284.
6. World Health Organization. Urticaria Fact Sheet. 2022.
7. Cleveland Clinic. Angioedema – Symptoms, Causes, and Treatment. Updated 2024.